Sommaire

Numéro précédent | Numéro suivant

• • ·Investing in autism: better evidence for better care

    Page :251

     
• • ·Approved drugs for multiple sclerosis: the challenge of choice

    Page :252-253

    Maria Pia Sormani, Alice Laroni

     
• • ·The relevance of atrial fibrillation in stroke prevention

    Page :253-255

    Fernando D Testai

    
• • ·Selective sodium channel blockers in trigeminal neuralgia

    Page :255-256

    Troels Staehelin Jensen

    
• • ·The cause of stroke matters for secondary prevention

    Page :256-257

    Hans-Christoph Diener

    
• • ·Solving the conundrum of insoluble protein aggregates

    Page :258-259

    Sonia George, Patrik Brundin

     
• • ·Ocrelizumab in multiple sclerosis: markers and mechanisms

    Page :259-261

    Reinhard Hohlfeld, Edgar Meinl

    
• • ·Corrections

    Page :261

    
• • ·Corrections

    Page :261

    
• • ·Corrections

    Page :261

    
• • ·Cognitive decline before diagnosis of Parkinson’s disease

    Page :262

    Sirwan KL Darweesh, Peter J Koudstaal, M Kamran Ikram, M Arfan Ikram

    
• • ·Cognitive decline before diagnosis of Parkinson’s disease – Authors’ reply

    Page :262

    Anette Schrag, Daniel Weintraub, Jonathan M Schott

    
• • ·Diagnosis and treatment of carpal tunnel syndrome

    Page :263

    J Grant Thomson

    
• • ·Diagnosis and treatment of carpal tunnel syndrome – Authors’ response

    Page :263-264

    Luca Padua, Daniele Coraci, Carmen Erra, Costanza Pazzaglia, Ilaria Paolasso, Claudia Loreti, Pietro Caliandro, Lisa D Hobson-Webb

    
• • ·Stakeholder collaboration for spinal muscular atrophy therapy development

    Page :264

    Annemieke Aartsma-Rus, Pavel Balabanov, Luca Binetti, Manuel Haas, Marion Haberkamp, Joanna Mitchell, Mário Miguel Rosa, Francesco Muntoni, Richard Finkel, Eugenio Mercuri

    
• • ·What about a seizure-alert dog?

    Page :265-266

    Adrian Burton

     
• • ·Samuel Wiebe: new President of the International League Against Epilepsy

    Page :267

    Adrian Burton

     
• • ·Keith Vossel

    Page :268

     
• • ·Neuropathies and diabetes in Jules Verne

    Page :268

    Antonio Perciaccante, Alessia Coralli, Philippe Charlier, Raffaella Bianucci, Otto Appenzeller

    
• • ·Memory, distraction, and nostalgia

    Page :269

    Peter Ranscombe

     
• • ·Richard Morris’ Christmas lecture double-bill

    Page :270

    Peter Ranscombe

     
• • ·Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

    Page :271-281

    Tomas Kalincik, J William L Brown, Neil Robertson, Mark Willis, Neil Scolding, Claire M Rice, Alastair Wilkins, Owen Pearson, Tjalf Ziemssen, Michael Hutchinson, Christopher McGuigan, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Raed Alroughani, Eugenio Pucci, Patrizia Sola, Raymond Hupperts, Jeannette Lechner-Scott, Murat Terzi, Vincent Van Pesch, Csilla Rozsa, François Grand’Maison, Cavit Boz, Franco Granella, Mark Slee, Daniele Spitaleri, Javier Olascoaga, Roberto Bergamaschi, Freek Verheul, Steve Vucic, Pamela McCombe, Suzanne Hodgkinson, Jose Luis Sanchez-Menoyo, Radek Ampapa, Magdolna Simo, Tunde Csepany, Cristina Ramo, Edgardo Cristiano, Michael Barnett, Helmut Butzkueven, Alasdair Coles, MSBase Study Group †

    Résumé Résumé Plan Plan   
• • ·Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF_RANDOMISED): an open-label randomised controlled trial

    Page :282-290

    Rolf Wachter, Klaus Gröschel, Götz Gelbrich, Gerhard F Hamann, Pawel Kermer, Jan Liman, Joachim Seegers, Katrin Wasser, Anna Schulte, Falko Jürries, Anna Messerschmid, Nico Behnke, Sonja Gröschel, Timo Uphaus, Anne Grings, Tugba Ibis, Sven Klimpe, Michaela Wagner-Heck, Magdalena Arnold, Evgeny Protsenko, Peter U Heuschmann, David Conen, Mark Weber-Krüger, Find-AFrandomised Investigators and Coordinators

    Résumé Résumé Plan Plan   
• • ·Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial

    Page :291-300

    Joanna M Zakrzewska, Joanne Palmer, Valerie Morisset, Gerard MP Giblin, Mark Obermann, Dominik A Ettlin, Giorgio Cruccu, Lars Bendtsen, Mark Estacion, Dominique Derjean, Stephen G Waxman, Gary Layton, Kevin Gunn, Simon Tate, study investigators

    Résumé Résumé Plan Plan   
• • ·Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial

    Page :301-310

    Pierre Amarenco, Gregory W Albers, Hans Denison, J Donald Easton, Scott R Evans, Peter Held, Michael D Hill, Jenny Jonasson, Scott E Kasner, Per Ladenvall, Kazuo Minematsu, Carlos A Molina, Yongjun Wang, K S Lawrence Wong, S Claiborne Johnston, SOCRATES Steering Committee and Investigators

    Résumé Résumé Plan Plan   
• • ·Epileptic activity in Alzheimer’s disease: causes and clinical relevance

    Page :311-322

    Keith A Vossel, Maria C Tartaglia, Haakon B Nygaard, Adam Z Zeman, Bruce L Miller

    Résumé Résumé Plan Plan  
• • ·The prion model for progression and diversity of neurodegenerative diseases

    Page :323-332

    Barbara E Stopschinski, Marc I Diamond

    Résumé Résumé Plan Plan